$0.6643
Insights on Compugen Ltd
In the last 1 year, Seagen, Inc. has given 75.9% return, outperforming this stock by 120.1%
In the last 3 years, Novo Nordisk A/s has given 25.4% return, outperforming this stock by 120.2%
1.08%
Downside
Day's Volatility :2.55%
Upside
1.49%
19.7%
Downside
52 Weeks Volatility :64.43%
Upside
55.7%
Period | Compugen Ltd | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -41.32% | -3.8% | 0.0% |
6 Months | -36.89% | 2.3% | 0.0% |
1 Year | -44.25% | -6.7% | -6.2% |
3 Years | -94.79% | 18.2% | -2.8% |
Market Capitalization | 56.7M |
Book Value | $0.6 |
Dividend Share | 0.0 |
Dividend Yield | 3.38% |
Earnings Per Share (EPS) | -0.37 |
PEG Ratio | 0.0 |
Wall Street Target Price | 4.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -460.07% |
Return On Assets TTM | -25.83% |
Return On Equity TTM | -47.44% |
Revenue TTM | 7.5M |
Revenue Per Share TTM | 0.09 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 6.5M |
EBITDA | -34.0M |
Diluted Eps TTM | -0.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.26 |
EPS Estimate Next Year | -0.52 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 603.0%
Sell
Neutral
Buy
Compugen Ltd is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Compugen Ltd | -2.34% | -36.89% | -44.25% | -94.79% | -80.66% |
![]() Moderna, Inc. | 6.67% | -37.2% | -55.08% | -48.27% | 324.78% |
![]() Regeneron Pharmaceuticals, Inc. | 3.98% | 10.98% | 7.57% | 56.69% | 121.14% |
![]() Novo Nordisk A/s | 5.81% | 27.65% | 63.72% | 203.89% | 337.58% |
![]() Seagen, Inc. | -0.29% | 10.06% | 75.9% | 25.37% | 241.2% |
![]() Vertex Pharmaceuticals Incorporated | -1.8% | 7.9% | 10.94% | 54.12% | 94.15% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Compugen Ltd | NA | NA | 0.0 | -0.26 | -0.47 | -0.26 | 0.03 | 0.6 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -11.52 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 43.04 | 43.04 | 2.03 | 2.62 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.52 | 26.52 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Compugen Ltd | Buy | $56.7M | -80.66% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $29.6B | 324.78% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 121.14% | 22.78 | 30.47% |
![]() Novo Nordisk A/s | Buy | $470.4B | 337.58% | 43.04 | 35.11% |
![]() Seagen, Inc. | Hold | $40.0B | 241.2% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $91.0B | 94.15% | 26.52 | 35.94% |
Compugen Ltd’s price-to-earnings ratio stands at None
Read Morecompugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. the company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program. the company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements, in both cases providing compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. compugen’s wholly-owned u.s. subsidiary located in south san francisco is developing monoclonal antib
Organization | Compugen Ltd |
Employees | 69 |
CEO | Dr. Anat Cohen-Dayag Ph.D. |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$0.66
-0.7%
Advisorshares Alpha Dna Equity Sentiment Etf
$0.66
-0.7%
Liberty Tripadvisor Hdg-b
$0.66
-0.7%
Tempo Automation Holdings Inc
$0.66
-0.7%
Falcon's Beyond Global Inc
$0.66
-0.7%
Jaguar Global Growth Corporation I
$0.66
-0.7%
Missfresh Ltd
$0.66
-0.7%
Shuaa Partners Acquisition Corp I
$0.66
-0.7%
Rose Hill Acquisition Corp
$0.66
-0.7%